Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:
“The modern management of Ph+ ALL has evolved dramatically, shifting from intensive chemotherapy-based regimens combined with TKIs toward chemotherapy-free or low-intensity approaches incorporating potent TKIs and immunotherapies: Here is the MDACC project for Ph+ALL.”
More posts featuring Mohamed Benlazar on OncoDaily.